BG108379A - Използване на енантиомерно чист есциталопрам - Google Patents
Използване на енантиомерно чист есциталопрам Download PDFInfo
- Publication number
- BG108379A BG108379A BG108379A BG10837903A BG108379A BG 108379 A BG108379 A BG 108379A BG 108379 A BG108379 A BG 108379A BG 10837903 A BG10837903 A BG 10837903A BG 108379 A BG108379 A BG 108379A
- Authority
- BG
- Bulgaria
- Prior art keywords
- escitalopram
- treatment
- pharmaceutical composition
- disorder
- disorders
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 52
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000015238 neurotic disease Diseases 0.000 claims abstract description 7
- 206010029333 Neurosis Diseases 0.000 claims abstract description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 3
- 208000032841 Bulimia Diseases 0.000 claims abstract description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 3
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims abstract description 3
- 208000022531 anorexia Diseases 0.000 claims abstract description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 3
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 3
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 208000019899 phobic disease Diseases 0.000 claims abstract description 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 3
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims abstract 2
- 208000030814 Eating disease Diseases 0.000 claims abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract 2
- 208000030990 Impulse-control disease Diseases 0.000 claims abstract 2
- 208000026345 acute stress disease Diseases 0.000 claims abstract 2
- 235000014632 disordered eating Nutrition 0.000 claims abstract 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 13
- 238000011221 initial treatment Methods 0.000 claims description 4
- 150000003891 oxalate salts Chemical class 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 229960001653 citalopram Drugs 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 208000019906 panic disease Diseases 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 206010041250 Social phobia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- 206010033664 Panic attack Diseases 0.000 description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940066010 citalopram 40 mg Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940041201 escitalopram 10 mg Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100684 | 2001-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108379A true BG108379A (bg) | 2004-11-30 |
Family
ID=8160464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108379A BG108379A (bg) | 2001-05-01 | 2003-11-24 | Използване на енантиомерно чист есциталопрам |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20040198809A1 (enExample) |
| EP (1) | EP1385503A1 (enExample) |
| JP (1) | JP2004527551A (enExample) |
| KR (2) | KR20100012089A (enExample) |
| CN (1) | CN1509169A (enExample) |
| AR (1) | AR033308A1 (enExample) |
| AT (1) | AT10974U1 (enExample) |
| BG (1) | BG108379A (enExample) |
| BR (1) | BR0208283A (enExample) |
| CA (1) | CA2445843A1 (enExample) |
| CZ (1) | CZ20033267A3 (enExample) |
| EA (1) | EA200301195A1 (enExample) |
| HR (1) | HRP20030744A2 (enExample) |
| HU (1) | HUP0400054A3 (enExample) |
| IL (1) | IL158031A0 (enExample) |
| IS (1) | IS6954A (enExample) |
| ME (1) | MEP5908A (enExample) |
| MX (1) | MXPA03008777A (enExample) |
| NO (1) | NO20034538D0 (enExample) |
| PL (1) | PL367480A1 (enExample) |
| SK (1) | SK14612003A3 (enExample) |
| UA (1) | UA82828C2 (enExample) |
| WO (1) | WO2002087566A1 (enExample) |
| YU (1) | YU85303A (enExample) |
| ZA (1) | ZA200307102B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
| MXPA05005772A (es) * | 2002-12-23 | 2005-08-16 | Lundbeck & Co As H | Bromhidrato de escitalopram y un metodo para su preparacion. |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| ES2515092T3 (es) * | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
| EA200601641A1 (ru) * | 2004-03-05 | 2006-12-29 | Х. Лундбекк А/С | Кристаллическая композиция, содержащая оксалат эсциталопрама |
| US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
| TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
| CA2625835A1 (en) | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
| US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| EP2086509A1 (en) * | 2006-10-20 | 2009-08-12 | Ratiopharm GmbH | Escitalopram and solid pharmaceutical composition comprising the same |
| JP5404048B2 (ja) * | 2006-10-27 | 2014-01-29 | 久光製薬株式会社 | 貼付剤 |
| EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
| MY157192A (en) * | 2007-08-03 | 2016-05-13 | Richter Gedeon Nyrt | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| EP2248808B1 (en) * | 2008-01-31 | 2014-07-16 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
| WO2010098230A1 (ja) * | 2009-02-27 | 2010-09-02 | 久光製薬株式会社 | 経皮投与製剤 |
| US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| EP3294337B1 (en) * | 2015-05-13 | 2024-12-18 | Arvid Carlsson Research AB | Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (enExample) * | 1965-03-18 | |||
| US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| UA62984C2 (en) * | 1997-11-11 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
| JP2002519321A (ja) * | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体 |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| SK285719B6 (sk) * | 1998-10-20 | 2007-07-06 | H. Lundbeck A/S | Spôsob prípravy citalopramu a medziprodukty |
| EP1173431B2 (en) * | 1999-04-14 | 2009-08-26 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| EP1276478A2 (en) * | 2000-04-24 | 2003-01-22 | ARYx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
-
2002
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0208283A (pt) | 2004-03-09 |
| US20040198810A1 (en) | 2004-10-07 |
| US20040198811A1 (en) | 2004-10-07 |
| MEP5908A (xx) | 2010-02-10 |
| NO20034538L (no) | 2003-10-09 |
| IL158031A0 (en) | 2004-03-28 |
| EP1385503A1 (en) | 2004-02-04 |
| US20040192764A1 (en) | 2004-09-30 |
| CZ20033267A3 (en) | 2004-06-16 |
| JP2004527551A (ja) | 2004-09-09 |
| UA82828C2 (en) | 2008-05-26 |
| KR20040030609A (ko) | 2004-04-09 |
| HUP0400054A3 (en) | 2007-03-28 |
| CN1509169A (zh) | 2004-06-30 |
| US20040192765A1 (en) | 2004-09-30 |
| US20040198809A1 (en) | 2004-10-07 |
| HRP20030744A2 (en) | 2005-06-30 |
| KR20100012089A (ko) | 2010-02-05 |
| MXPA03008777A (es) | 2004-02-12 |
| WO2002087566A1 (en) | 2002-11-07 |
| AT10974U1 (de) | 2010-02-15 |
| YU85303A (sh) | 2006-05-25 |
| CA2445843A1 (en) | 2002-11-07 |
| IS6954A (is) | 2003-09-15 |
| US20080004338A1 (en) | 2008-01-03 |
| US20040192766A1 (en) | 2004-09-30 |
| NO20034538D0 (no) | 2003-10-09 |
| AR033308A1 (es) | 2003-12-10 |
| EA200301195A1 (ru) | 2004-04-29 |
| HUP0400054A2 (hu) | 2004-04-28 |
| PL367480A1 (en) | 2005-02-21 |
| SK14612003A3 (sk) | 2004-04-06 |
| ZA200307102B (en) | 2004-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108379A (bg) | Използване на енантиомерно чист есциталопрам | |
| HU208484B (en) | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia | |
| CN102438603A (zh) | 少肌症的预防和治疗 | |
| BRPI0610509A2 (pt) | tratamento de dependência a drogas | |
| JP2022552808A (ja) | Ｇａｂａ－ａ受容体陽性アロステリック調節因子と、ｎｍｄａ拮抗薬、ｎｍｄａ陰性アロステリック調節因子、またはｎｍｄａ部分作動薬との組み合わせ | |
| JP2007513052A (ja) | セロトニン再取り込み阻害剤およびアゴメラチンの併用。 | |
| CN104736151A (zh) | 纤维化的柚皮素和积雪草酸组合治疗 | |
| US20150335649A1 (en) | Low dosage combinations of fluoxetine and reboxetine for treating obesity | |
| Simon et al. | Citalopram for social phobia: a clinical case series | |
| AU2002254870A1 (en) | The use of enantiomeric pure escitalopram | |
| AU2008201217A1 (en) | The use of enantiomeric pure escitalopram | |
| JP2002524509A (ja) | 新規組成物 | |
| US20070123584A1 (en) | Method of treating premenstrual dysphoric disorder with escitalopram | |
| HK1067047A (en) | The use of enantiomeric pure escitalopram | |
| WO2025219389A1 (fr) | Compositions contenant une combinaison synergique de mémantine et de vitamine d | |
| JP2009545573A (ja) | サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン／ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物 | |
| RU2024122065A (ru) | Композиции и способы лечения депрессии | |
| HRP20100463A2 (hr) | Upotreba čistog enantiomernog citaloprama | |
| KR101736846B1 (ko) | 급성관동맥증후군에 동반되는 우울증 치료용 약제학적 조성물 | |
| WO2023236781A1 (zh) | 治疗精神类疾病的方法 | |
| CN118401239A (zh) | 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮 | |
| WO2003072093A1 (en) | METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs) | |
| Iancu et al. | THE ROLE OF SEROTONIN IN DEPRESSION AND ANXIETY DISORDERS | |
| De Nayer et al. | P01. 42 Symptom relief obtained with venlafaxine versus fluoxetine in depressed patients with concomitant anxiety | |
| De Clercq et al. | P01. 41 Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment |